Comparative Pharmacology
Head-to-head clinical analysis: MACUGEN versus SUSVIMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACUGEN versus SUSVIMO.
MACUGEN vs SUSVIMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegaptanib is a pegylated modified oligonucleotide that binds to and inhibits vascular endothelial growth factor (VEGF-165), reducing angiogenesis and vascular permeability.
Ranibizumab is a humanized monoclonal antibody fragment that binds to and inhibits the activity of vascular endothelial growth factor A (VEGF-A), thereby reducing angiogenesis and vascular permeability.
Intravitreal injection of 0.3 mg (0.09 mL) once every 6 weeks.
10 mg administered via intravitreal injection every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
None Documented
None Documented
The terminal elimination half-life in plasma is approximately 10 days following intravitreal administration, consistent with slow clearance from the vitreous cavity and systemic absorption.
Terminal elimination half-life is approximately 4.9 days (range 3.5–6.7 days) in patients receiving intravitreal injections every 4 weeks. The long half-life supports sustained intravitreal VEGF suppression with monthly dosing.
Pegaptanib is eliminated primarily via renal excretion, with the parent compound and metabolites excreted in urine accounting for >90% of the administered dose. Biliary/fecal elimination is negligible (<5%).
Primarily metabolized in the liver via catabolism to small peptides and amino acids; renal elimination of metabolites is negligible as intact drug is not excreted renally. Biliary/fecal excretion is not a significant route. <1% of dose excreted unchanged in urine.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor